Last reviewed · How we verify
SM17
At a glance
| Generic name | SM17 |
|---|---|
| Sponsor | SinoMab BioScience Ltd |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study to Evaluate SM17 in Healthy Participants (PHASE1)
- A Clinical Study to Evaluate SM17 for Atopic Dermatitis (PHASE2)
- A Phase I Clinical Study to Evaluate SM17 in Chinese Healthy Subjects and Patients With Moderate to Severe Atopic Dermatitis (PHASE1)
- A Phase 1 Study of Single and Multiple Intravenous Doses of SM17 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SM17 CI brief — competitive landscape report
- SM17 updates RSS · CI watch RSS
- SinoMab BioScience Ltd portfolio CI